Canopy Growth Corporation

Canopy Growth Corporation Earnings Recaps

WEED.TO Health Care 1 recap
Next earnings: August 7, 2026 (estimated) · full calendar
Q3 2026 Feb 6, 2026

Canopy Growth demonstrated solid financial progress in Q3 FY2026, achieving its narrowest adjusted EBITDA loss to date while simultaneously enhancing its balance sheet and operational efficiency. The company is well-positioned for future growth, particularly in medical cannabis and international markets.

Key takeaways
  • Adjusted EBITDA loss narrowed significantly, reflecting ongoing cost discipline and improved execution.
  • Canadian medical revenue increased by 15% year-over-year, marking the sixth consecutive quarter of growth.
  • The planned acquisition of MTL Cannabis aims to strengthen Canopy's leadership in Canadian medical cannabis and expand its presence in Quebec's adult-use market.
  • Net revenue from international operations increased by 22% sequentially, indicating positive momentum in global markets.
  • A recapitalization effort successfully bolstered liquidity, extending debt maturities to 2031 and enhancing financial flexibility.
Full recap

Go deeper on WEED.TO and the wider market.

All earnings recaps Browse the latest results across the market. Stock directory Browse companies by sector and market. Highest-yield stocks A curated screen of top dividend payers. Investing glossary Plain-English definitions for every metric.